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Abstract 
 
 A new type of dirhodium paddlewheel complexes were synthesized that contain 
ligands with extended π-systems.  These ligands are expected to increase the affinity of 
these complexes for DNA because they are known to intercalate between the DNA bases 
in related systems. In addition, the new complexes possess equatorial acetonitrile ligands 
that exchange for water molecules upon photolysis, which produces an activated form of 
the complex that is able to bind covalently to DNA. These features lead to dual-binding 
through covalent binding to DNA upon irradiation and intercalation of the extended π-
system ligand between the DNA bases. Currently, there are no reports of photoactivated 
dual-binding agents. These complexes possess features desired of photodynamic therapy 
agents, primarily because they are inactive in the dark, and readily bind to DNA when 
irradiated. 
The dirhodium bis-amidate complexes cis-H,H-[Rh2(HNOCCH3)2(bpy)(CH3CN)4][BF4]2 
(bpy = 2,2´-bipyridine) and cis-H,H-[Rh2(HNOCCH3)2(dpq)(CH3CN)4][BF4]2 (dpq = 
dipyrido[3,2-f:2',3'-h]-quinoxaline) were successfully synthesized from cis-H,H-
[Rh2(HNOCCH3)2(CH3CN)6][BF4]2 with the corresponding bidentate ligand.  The bpy 
complex was prepared in 7 days, and because it cannot intercalate between the DNA 
bases, it is used as a control for no intercalation, but it was shown to bind covalently to 
DNA upon irradiation. The dpq complex was synthesized successfully in 1 day. Studies 
 ii 
 
of this complex are underway and its intercalation ability has not yet been proven. The 
synthesis of related complexes with other bidentate ligands is ongoing. 
The preparation of complexes possessing acetate bridging ligands instead of amidates 
were attempted from the reaction of cis-[Rh2(CH3COO)2(CH3CN)6]
2+
 and bpy. Cis-
[Rh2(CH3COO)2(bpy)(CH3CN)4]
2+
  was not successfully synthesized, but it is still of 
interest, since its precursor cis-[Rh2(CH3COO)2(CH3CN)6]
2+
 binds to DNA upon 
irradiation and it is inactive under dark conditions. 
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Chapter 1: Introduction and Background 
 
 Photodynamic therapy (PDT) achieves high level of selectivity for malignant 
cells, resulting in low levels systemic toxicity and low levels of invasiveness, through the 
use of light activated cytotoxins
1
. PDT has been used to treat lung, bladder and ovarian 
cancer quite effectively
2
. PDT uses organic drugs, which are oxygen dependent. 
Photofrin
®
, an FDA-approved chemotherapy PDT agent, it is excited from the ground 
singlet state which decays to form an excited triplet state following irradiation. When the 
excited triplet state relaxes to the singlet ground state, it transfers energy to triplet 
molecular oxygen, 
3
O2, producing singlet oxygen, 
1
O2. Singlet oxygen is toxic and causes 
damage to biomolecules, resulting in cell death
3
. The mechanism of action of Photofrin
®
 
is shown in Figure 1. 
 
Figure 1. Mechanism of action of Photofrin®. 
 2 
 
Because of the requirement of oxygen in tissue to generate the damaging species, organic 
PDT agents are not operable in hypoxic tissues. Tumors, because of the accelerated cell 
growth and metabolic demands, have a low concentration of molecular oxygen
4
. This is 
one of the main drawbacks of organic PDT agents. Transition metal complexes have now 
received more attention because they have the potential to operate via a different mode of 
action than organic PDT agents. 
Another FDA-approved chemotherapy agent is Cisplatin
®
, cis-
diamminedichloroplatinum(II). Cisplatin
®
 undergoes thermal ligand exchange, in which 
one or both of the chlorides are exchanged for water to form the activated complexes cis-
[Pt(NH3)2(H2O)Cl]
+ 
and cis-[Pt(NH3)2(H2O)2]
+ 
 which bind irreversibly to DNA
5
. These 
activated complexes bind to purines in DNA, most commonly guanine, forming 1,2-
intrastrand adducts that kink DNA and inhibit the activity of DNA polymerases. The 1,2-
intrastrand adducts formed with the platinum complex are unable to be repaired by 
excision repair systems in the cell, so the cell is targeted to death. The mechanism of 
action of Cisplatin
®
 is shown in Figure 2. The main disadvantage of Cisplatin is that, as 
mentioned, is thermally activated and it causes damage to both healthy and malignant 
cells. 
 
Figure 2. Mechanism of action of Cisplatin® 
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Only two analogs of Cisplatin
®
 have been approved by the FDA: Carboplatin
®
 (cis-
diammine(1,1-cyclobutanedicarboxylato)platinum(II)) and Oxaliplatin
®
 ([(1R,2R)-
cyclohexane-1,2-diamine](ethanedioato-O,O')platinum(II)), shown in Figure 3. 
 
Figure 3. FDA-approved Cisplatin® analogs (a) Carboplatin® and (b) Oxaliplatin® 
 
Dual-Binding action refers to the ability of a complex to be able to both bind covalently 
to DNA by coordination and to intercalate extended π-system ligands in between the 
DNA bases. Such dual binding has been shown to be important in platinum complexes 
for activity towards Cisplatin-resistant cell lines
6
. It has been shown that one dirhodium 
bis-acetate complex also has this dual-binding ability
7
. Cis-[Rh2(dap)(µ-O2CCH3)2(η
1
-
O2CCH3)-(CH3OH)](O2CCH3) (dap = 1,12-diazaperylene), shown in Figure 4, was 
determined by 2D-NOESY NMR spectroscopy to covalently bind to adenine N7 and to 
intercalate between adjacent adenines (A) of a 12-mer duplex. The increase of distance 
between A6H8 and A7H8 was observed as the correlation between these two protons 
decreased significantly after intercalation of the dap ligand. The covalent binding was 
shown by 
1
H NMR Spectroscopy, where one of the rhodium atoms bind to the A6 residue 
of the d(CTCTCAACTTCC) 12-mer studied. 
 4 
 
The drawback of this dual-binding complex is that is thermally activated because the 
equatorial CH3OH and η
1
-CH3COO
-
 ligands readily exchange. This is undesired, since 
toxicity should be controlled and the complex should only be activated to act on 
malignant cells. 
 
Figure 4. (a) Dual-binding complex cis-[Rh2(dap)(µ-O2CCH3)2(η
1
-O2CCH3)-
(CH3OH)](O2CCH3) (b) dap ligand (dap = 1,12-diazaperylene) 
 
The dirhodium core complexes studied presented in this work are expected to be dual-
binding photodynamic therapy agents. The dual-action in these complexes is also 
intercalation and covalent binding; however, in this case covalent binding is triggered by 
irradiation of the compounds. Currently, there are no reports of dual-binding 
photoactivated complexes. In addition, PDT agents that have novel DNA binding modes 
may be active against cisplatin-resistant cell lines
6
, so the study of these complexes may 
lead to new drugs whose mode of action differs significantly from those currently 
available.  
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The main considerations for successful PDT agents are
8
: 
 Complexes should be activated with irradiation in the “PDT Window” (600-850 
nm), because this range results in greater tissue penetration. 
 The photolysis process should be rapid and efficient, with high quantum yield (Ф) 
of the desired reaction. 
 PDT agents must be inactive in the dark, but the photo-products should bind DNA 
readily. 
The types of complex explored in this research are shown in Figure 5 and the ligands of 
interest are shown in Figure 6. 
 
Figure 5. Complexes involved in this research: (a) Rh2(CH3COO)4 (b) cis-
[Rh2(CH3COO)2(CH3CN)6]
2+
 (c) H,H (H,H = cis-H,H-[Rh2(HNOCCH3)2(CH3CN)6]
2+
 
(d) cis-[Rh2(OOCCH3)2(N-N)(CH3CN)4]
2+
 where N-N = bpy, dpq, dppz, dppn (e) H,H-
(N-N) where N-N = bpy, dpq, dppz. All Lax and Leq represent axially and equatorially 
bound CH3CN, respectively. 
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Figure 6. Ligands of interest: (a) bpy (bpy = 2,2’-bipyridine) (b) dpq (dpq = 
dipyrido[3,2-f:2',3'-h]-quinoxaline) (c) dppz (dppz = dipyrido[3,2-a:2’,3’-c]phenazine) 
(d) dppn (dppn = benzo[i]-dipyrido[3,2-a:2’,3’-c]phenazine) 
 
The precursors of the complexes synthesized in this study have shown to have properties 
desired for PDT agents. The complex cis-[Rh2(CH3COO)2(CH3CN)6]
2+ 
was shown to be 
inactive in the dark and to bind to DNA upon irradiation
9
.  
To generate dual-binding agents, two of the Rh-CH3CNeq bound a rhodium atom are 
exchanged for a bidentate ligand to form cis-[Rh2(CH3COO)2(N-N)(CH3CN)4]
2+
, where 
N-N = dqp, dppz, dppn. The extended π-systems in the dpq, dppz, and dppn ligands are 
expected to intercalate between the DNA bases, which will increase the affinity of the 
dirhodium complexes for DNA. The photoactivated binding is initiated by the exchange 
of the remaining two Rh-CH3CNeq ligands for water molecules upon irradiation, followed 
by the facile thermal exchange water ligand(s) for DNA bases. 
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Chapter 2: Dirhodium Bis-Amidate Complexes 
 
2.1 Materials 
 
Reagents: 1,10-phenanthroline-5,6-dione, ethylenediamine, o-phenylenediamine, bpy 
(bpy = 2,2’-bipyridine) were purchased from Sigma-Aldrich. Solvents: methanol, 
acetonitrile, diethyl ether, all purchased from Sigma-Aldrich, dichloromethane purchased 
from Mallinckrodt Chemicals. 
1
H NMR solvents: acetonitrile-d3 and deuterium oxide all 
purchased from Sigma-Aldrich. All reagents and solvents were used as purchased. 
The complex H,H (H,H = cis-H,H-[Rh2(HNOCCH3)2(CH3CN)6][BF4]2) was synthesized 
by Scott Burya
10
. 
 
2.2 Instrumentation 
 
Electrospray ionization mass spectrometry (ESI-MS) data were acquired on a Bruker 
MicroTOF spectrometer and 
1
H NMR spectra were collected using a Bruker 400 MHz 
Avance III or a Bruker 250 MHz DPX. 
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2.3 Synthesis and Characterization 
2.3.1 Ligand Synthesis 
2.3.1.1 Synthesis of dipyrido[3,2-f:2',3'-h]-quinoxaline (dpq) 
The ligand dpq (dpq = dipyrido[3,2-f:2',3'-h]-quinoxaline) was synthesized from 1,10-
phenanthroline-5,6-dione and ethylenediamine by a published procedure
11
. A solution of 
ethylenediamine (9.3 mg, 1.55 mmol) and 1,10-phenanthroline-5,6-dione (194.4 mg, 
0.925 mmol) in ethanol (65 mL) was stirred at 40˚C for 3 h and then at room temperature 
overnight. The solvent was evaporated under reduced pressure, and the resulting solid 
was recrystallized from methanol to yield dpq (178.3 mg, 0.77 mmol, 83% yield). The 
product was characterized by 
1
H NMR (250 MHz, acetonitrile-d3). The NMR spectrum is 
shown in Figure 7. 
 
Figure 7. 
1
H NMR spectrum of dpq (250 MHz, acetonitrile-d3) 
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2.3.1.1 Synthesis of dipyrido[3,2-a:2’,3’-c]phenazine (dppz) 
The ligand dppz (dppz = dipyrido[3,2-a:2’,3’-c]phenazine) was synthesized from 1,10-
phenanthroline-5,6-dione and o-phenylenediamine by a published procedure
12
. A solution 
of o-phenylenediamine (66.1 mg, 0.61 mmol) and 1,10-phenanthroline-5,6-dione (65.6 
mg, 0.31 mmol) in ethanol (15 mL) was boiled for 5 min. The solution was then cooled 
down slowly in an ice bath and the resulting solid was filtered and washed with cold 
ethanol (3 x 5mL). The resulting solid was recrystallized from ethanol to yield dppz (67.2 
mg, 0.24 mmol, 76% yield). The product was characterized by 
1
H NMR (250 MHz, 
acetonitrile-d3). The NMR spectrum is shown in Figure 8. 
 
Figure 8. 
1
H NMR spectrum of dppz (250 MHz, acetonitrile-d3) 
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2.3.2 Synthesis of Dirhodium Bis-Amidate Complexes 
2.3.2.1 Synthesis of cis-H,H-[Rh2(HNOCCH3)2(bpy)(CH3CN)4][BF4]2 
The complex H,H-bpy (H,H-bpy = cis-H,H-[Rh2(HNOCCH3)2(bpy)(CH3CN)4][BF4]2) 
was synthesized from H,H (H,H = cis-H,H-[Rh2(HNOCCH3)2(CH3CN)6][BF4]2) and bpy 
(bpy = 2,2’-bipyridine). In order to determine the ideal reaction time, H,H (10.0 mg, 13.5 
µmol) was dissolved in acetonitrile (2.5 mL) and stirred covered from light with 
aluminum foil. A solution of bpy (11.8 mg, 75.6 µmol) in acetonitrile (1.0 mL) was 
added to the H,H solution and the mixture was stirred covered from light at room 
temperature. After 24 h, a 0.875 mL aliquot was taken from the reaction mixture and 
excess diethyl ether was added to the aliquot and a precipitate formed. The mixture was 
sonicated and then centrifugated, and the supernatant was discarded with a pipette. The 
precipitate was washed by adding excess diethyl ether, then sonicating and centrifugating 
the mixture. The supernatant was discarded and the resulting solid was redissolved in a 
minimal volume of acetonitrile. The solution was sonicated and centrifugated. The 
precipitate was then discarded and the supernatant was dried under a stream of air. The 
same procedure was also repeated after 3 days, 7 days and 8. The resulting solids from 
each aliquot were studied by 
1
H NMR (400 MHz, deuterium oxide) to determine the 
purity of the product at each reaction time. The NMR spectra are shown in Figure 9, 
which indicate that after 7 days, only one product is observed in the 
1
H NMR spectrum, 
consistent with H,H-bpy. 
After the ideal time for the synthesis of H,H-bpy was determined, H,H (20 mg, 27.0 
µmol) was dissolved in acetonitrile (5.0 mL) and covered from light. A solution of bpy 
 11 
 
(23.6 mg, 151.2 µmol) in acetonitrile (2.0 mL) was added to the H,H solution and was 
allowed to react in the dark at room temperature for 7 days. Excess diethyl ether was 
added to the solution and a precipitate formed. The mixture was sonicated and then 
centrifugated.  
 
 
Figure 9. 
1
H NMR (400 MHz, deuterium oxide) spectra of reaction of H,H with bpy after 
(a) 1 day, (b) 3 days, (c) 7 days, (d) 8 days. 
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The supernatant was discarded with a pipette, and the precipitate was washed by adding 
excess diethyl ether, then sonicating and centrifugating the mixture. The supernatant was 
discarded and the resulting solid was redissolved in a minimal volume of acetonitrile. The 
solution was sonicated and centrifugated. The precipitate was discarded and the 
supernatant was dried under a stream of air to yield H,H-bpy (13.7 mg, 16.8 µmol, 62 % 
yield). The product was characterized by 
1
H NMR spectroscopy (400 MHz, deuterium 
oxide) and spectrum is shown in Figure 10. 
 
 
 
 
Figure 10. 
1
H NMR (400 MHz, deuterium oxide) of H,H-bpy. The –NH peak is not seen 
in the spectrum. 
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The H,H-bpy product was also characterized by ESI-MS. The mass spectrum of the 
product is shown in Figure 11. The parent ion, [Rh2(HNOCCH3)2(bpy)(CH3CN)2]
2+
, was 
observed at m/z = 280.0, and the peak observed at m/z = 259.5 corresponds to the loss of 
one acetonitrile ligand, [Rh2(HNOCCH3)2(bpy)(CH3CN)]
2+
. The identities of the other 
peaks remain unknown. 
 
Figure 11. ESI-MS spectrum of H,H-bpy complex. 
 
2.3.2.2 Synthesis of cis-H,H-[Rh2(HNOCCH3)2(dpq)(CH3CN)4][BF4]2 
The complex H,H-dpq (H,H-dpq = cis-H,H-[Rh2(HNOCCH3)2(dpq)(CH3CN)4][BF4]2) 
was synthesized from H,H and dpq. In order to determine the ideal reaction time, H,H 
(10.0 mg, 13.5 µmol) was dissolved in acetonitrile (2.5 mL) and stirred covered from 
light with aluminum foil. A suspension of dpq (4.7 mg, 20.3 µmol) in acetonitrile (1.0 
mL) was added to the H,H solution and the mixture was stirred covered from light at 
room temperature. After 24 h, a 0.875 mL aliquot was taken from the reaction mixture. 
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Excess diethyl ether was added to the aliquot and a precipitate formed. The mixture was 
sonicated and then centrifugated. The supernatant was discarded with a pipette. The 
precipitate was washed by adding excess diethyl ether, then sonicating and centrifugating 
the mixture. The supernatant was discarded and the resulting solid was redissolved in a 
minimal volume of acetonitrile. The solution was sonicated and centrifugated. The 
precipitate was discarded and the supernatant was dried under a stream of air. The same 
procedure was repeated after 3 days and 7 days the reaction was started. The resulting 
solids from aliquot were studied by 
1
H NMR (400 MHz, deuterium oxide) to determine 
the purity of the product at each reaction time. The NMR spectra are shown in Figure 12. 
All the reactions showed the formation of H,H-dpq, however, in the 
1
H NMR spectra, 
undesired products and impurities were also observed.  
In order to determine the optimal method to obtain a clean product, the reaction was 
repeated as described above, but washing with excess dichloromethane after washing 
with diethyl ether and before dissolving in minimal acetonitrile. This process was 
performed on the reaction after 1 day and after 3 days. The 
1
H NMR (400 MHz, 
deuterium oxide) spectra of these reactions are shown in Figure 13. After 1 day, after 
washing with dichloromethane, only one product was observed in the 
1
H NMR spectrum. 
After 3 and 7 days, H,H-dpq was the primary product observed, however, vestiges of 
H,H-(dpq)2 were also observed after the dichloromethane wash. 
 15 
 
 
Figure 12. 
1
H NMR spectra of H,H reaction with dpq after (a) 1 day, (b) 7 days without 
washing with dichloromethane. The resonances marked with P correspond to the desired 
product, H,H-dpq complex. The resonances marked with an asterisk (*) correspond to 
impurities (undesired products, unreacted starting material). 
 
Figure 13. 
1
H NMR spectra of H,H reaction with dpq after (a) 1 day, (b) 3 (c) 7 days 
washing with dichloromethane during the workup. The resonances marked with an 
asterisk (*) correspond to impurities (undesired products, unreacted starting material). 
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A comparison of the reaction after 1 day with and without dichloromethane wash is 
shown in Figure 14.  
After 1 day, the desired product H,H-dpq is formed, however, H,H-(dpq)2 is also 
observed by 
1
H NMR spectroscopy. Washing with dichloromethane removes H,H-(dpq)2, 
however, it also dissolves some of the H,H-dpq complex. The dichloromethane wash 
reduces the yield of H,H-dpq, but makes it possible to obtain a clean product. 
 
 
 
Figure 14. 
1
H NMR spectra of H,H reaction with dpq after 1 day (a) washing with 
dichloromethane during workup, and (b) not washing with dichloromethane during 
workup. The resonances marked with an asterisk (*) correspond to impurities (undesired 
products, unreacted starting material). 
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In order to determine the optimal ratio of dpq ligand to H,H complex, a solution of H,H 
(5.0 mg, 6.75 µmol) in acetonitrile (1.25 mL) was stirred covered from light at room 
temperature. A suspension of dpq (1.6 mg, 6.90 µmol) in acetonitrile (0.5 mL) was added 
to the H,H solution and reacted at room temperature, covered from light. After 1 day and 
3 days, an aliquot of 0.875 mL was taken and treated as described above, without 
washing with dichloromethane. The 
1
H NMR (400 MHz, deuterium oxide) of the 
reactions are shown in Figure 15, comparing the conditions to the previous reaction with 
different dpq ligand to H,H complex ratio. 
 
Figure 15. 
1
H NMR spectra of H,H reaction with dpq after 1 day and 3 days. (a) and (c) 
reacting H,H with excess dpq. (b) and (d) reacting H,H with bpy in 1:1 ratio. The 
resonances marked with an asterisk (*) correspond to impurities (undesired products, 
unreacted starting material). 
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After the ideal conditions for the synthesis of H,H-dpq were determined, H,H (20 mg, 
27.0 µmol) was dissolved in acetonitrile (5.0 mL) and covered from light. A suspension 
of dpq (9.7 mg, 40.5 µmol) in acetonitrile (2.0 mL) was added to the H,H solution and 
reacted in the dark at room temperature for 7 days. Excess diethyl ether was added to the 
solution and a precipitate formed. The mixture was sonicated and then centrifugated. The 
supernatant was discarded with a pipette. The precipitate was washed by adding excess 
diethyl ether, then sonicating and centrifugating the mixture. The precipitate was then 
washed with excess dichloromethane, sonicating and centrifugating after adding the 
respective solvent. The supernatant was discarded and the resulting solid was redissolved 
in a minimal volume of acetonitrile. The solution was sonicated and centrifugated. The 
precipitate was discarded and the supernatant was dried under a stream of air to yield 
H,H-dpq (11.3 mg, 10.9 µmol, 40 % yield). The product was characterized by 
1
H NMR 
(400 MHz, deuterium oxide). The NMR spectrum is shown in Figure 16. 
 
Figure 16. 
1
H NMR spectrum of H,H-dpq complex (400 MHz, deuterium oxide). The –
NH peak is not seen in the spectrum. 
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The product was also characterized by ESI-MS. The mass spectrum of the product is 
shown in Figure 17. The parent ion (and base peak), 
[Rh2(HNOCCH3)2(dpq)(CH3CN)2]
2+
, was observed at m/z = 318.0. The identities of the 
other peaks are unknown. 
 
Figure 17. ESI-MS spectrum of H,H-dpq complex. 
 
2.4 Discussion 
The dirhodium H,H-bpy and H,H-dpq complexes were synthesized from the reaction of 
the H,H complex with excess of each respective ligand. The substitution of two 
coordinated acetonitrile molecules for the bidentate N-N ligands takes places trans to the 
nitrogen atoms of the amidate bridge. This can be rationalized by studying the bond 
lengths of the H,H complex. The Rh-CH3CNax bond lengths are 2.242(4) Å on average, 
and the Rh-CH3CNeq
O
 and Rh-CH3CNeq
N
 bonds are on average, 2.004(4) and 2.026(4) 
Å
10
. The longer Rh-CH3CN axial bonds are expected, since axial acetonitrile ligands 
undergo thermal exchange readily in water
9,10
. Now, comparing the equatorial acetonitrile 
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ligands that can be substituted for a bidentate N-N ligand, the Rh-CH3CNeq
N 
are longer 
than the Rh-CH3CNeq
O
, which may be related to the preference for substitution trans to 
the nitrogen atoms of the amidate bridge. 
It is important to mention that the thermal exchange of the Rh-CH3CNax for water in 
solution do not activate the complex for DNA binding. This is an advantage of this new 
type of complexes over Cisplatin, which is thermally activated to bind DNA, causing low 
selectivity and affecting both regular and malignant cells. 
Photolysis followed by the changes to the electronic absorption spectrum in water of the 
precursor complexes H,H and H,H-bpy over 60 min, λirr ≥ 495 nm, show that both of 
these species undergo ligand exchange
10,13
. In the case of the H,H complex, both Rh-
CH3CNeq
N
  and Rh-CH3CNeq
O
 exchanged upon irradiation in water to form cis-H,H-
[Rh2(HNOCCH3)2(CH3CN)3(H2O)3]
2+
. In the case of the H,H-bpy complex, only the Rh-
CH3CNeq
O
 ligands are available for exchange upon irradiation to form cis-H,H-
[Rh2(HNOCCH3)2(bpy)(CH3CN)(H2O)3]
2+
. This type of exchange triggered by 
irradiation is critical for DNA binding. In order to covalently bind to DNA, the Rh-
CH3CNeq  ligands need to exchanged for solvent water molecules so that covalent binding 
to DNA occurs where the water is incorporated after photolysis, followed by replacement 
by a nucleobase of the DNA double helix. 
Regarding the dual-binding action of the dirhodium bis-amidate complexes, a DNA 
binding gel assay of the H,H-bpy complex shows no change in mobility of DNA in the 
dark control, and reduced mobility of DNA upon irradiation for 30 min, λirr≥  395 nm
13
. 
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This suggests that cis-H,H-[Rh2(HNOCCH3)2(N-N)(CH3CN)4]
2+
 (N-N = bpy, dpq, dppz) 
can bind covalently to DNA only upon irradiation and cannot bind covalently in the dark, 
a desired feature of PDT agents. 
The H,H-bpy is a control for the second mode of action of the dual-binding agents: 
intercalation. The π-system of the bpy ligand is not extended enough to intercalate in 
between the DNA bases. Regarding the H,H-dpq complex, DNA binding assays are 
underway. The synthesis of H,H-dppz is underway in order to perform the same type of 
DNA studies mentioned above. 
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Chapter 3: Dirhodium Bis-Acetate Complexes 
 
3.1 Materials 
 
Reagents: rhodium (III) chloride trihydrate was purchased from Pressure Chemicals Co. 
2,3-naphthalenediamine was purchased from Spectrum. 1,10-phenanthroline-5,6-dione, 
sodium acetate trihydrate, triethyloxonium tetrafluoroborate (TEO), bpy (bpy = 2,2’-
bipyridine) were all purchased from Sigma-Aldrich. Solvents: ethanol (200 proof) was 
purchased from Decon Labs. Methanol, diethyl ether, and acetonitrile were all purchased 
from Sigma-Aldrich. Glacial acetic acid and dichloromethane were purchased from 
Mallinckrodt Chemicals. 
1
H NMR solvents: methanol-d4, acetonitrile-d3, chloroform-d, 
deuterium oxide were all purchased from Sigma-Aldrich. 
The ligand dpq (dpq = dipyrido[3,2-f:2',3'-h]-quinoxaline) was previously synthesized by 
the method described in chapter 2. 
 
3.2 Synthesis and Characterization 
3.2.1 Ligand Synthesis 
3.2.1.1 Synthesis of benzo[i]-dipyrido[3,2-a:2’,3’-c]phenazine (dppn) 
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The ligand dppn (dppn = benzo[i]-dipyrido[3,2-a:2’,3’-c]phenazine) was synthesized 
from 1,10-phenanthroline-5,6-dione and 2,3-naphthalenediamine by a modified published 
procedure
12
. A solution of 2,3-naphthalenediamine (112.0 mg, 0.71 mmol) and 1,10-
phenanthroline-5,6-dione (72.0 mg, 0.34 mmol) in ethanol (8.0 mL) was boiled for 15 
min. The solution was then cooled down slowly in an ice bath and the resulting solid was 
filtered and washed with cold ethanol (3 x 5mL) to yield dppn (70.1 mg, 0.21 mmol, 62 
% yield) as an orange solid. The product was characterized by 
1
H NMR (250 MHz, 
chloroform-d). The NMR spectrum is shown in Figure 18. 
 
 
 
 
Figure 18. 
1
H NMR spectrum of dppn (250 MHz, chloroform-d) 
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3.2.2 Synthesis of Dirhodium Bis-Acetate Complexes 
3.2.2.1 Synthesis of Rh2(CH3COO)4 
Rh2(CH3COO)4 was synthesized from RhCl3·3H2O, sodium acetate trihydrate and glacial 
acetic acid by a published procedure
14
. A mixture of RhCl3·3H2O (91.5 mg, 0.35 mmol), 
CH3COONa·3H2O (183.8 mg, 1.36 mmol) and glacial acetic acid (10 mL) was refluxed 
for 1 h in ethanol (200 proof, 10 mL). The solvent was then evaporated under reduced 
pressure and the resulting solid was transferred to a centrifugation vial with methanol. 
The solution was then cooled down in the freezer. The mixture was centrifugated and the 
supernatant was removed with a pipette and discarded. The precipitate was dried in the 
oven at 80˚C overnight to yield Rh2(CH3COO)4 (51.8 mg, 0.12 mmol, 68 % yield) as an 
emerald green solid. The product was characterized by 
1
H NMR (250 MHz, methanol-
d4). The NMR spectrum is shown in Figure 19. 
 
Figure 19. 
1
H NMR spectrum of Rh2(OOCCH3)4. (250 MHz, methanol-d4) 
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3.2.2.2 Synthesis of cis-[Rh2(CH3COO)2(CH3CN)6][BF4]2 
Cis-[Rh2(CH3COO)2(CH3CN)6][BF4]2 was synthesized from Rh2(CH3COO)4 and 
triethyloxonium tetrafluoroborate (TEO) by a modified published procedure
15
. A mixture 
of Rh2(CH3COO)4 (19.8 mg, 0.044 mmol) and triethyloxonium tetrafluoroborate (1M,  
175 µL, 0.175 mmol) was reacted at 45˚C for 5 h in acetonitrile (1.0 mL). The solvent 
was then evaporated under a stream of air and resulting solid was washed with 
dichloromethane (3 x 5 mL) and with diethyl ether (2 x 5 mL), centrifugating and 
removing the supernatant with a pipette after each wash. The resulting solid was 
dissolved in a minimal volume of acetonitrile and transferred to a vial. The solvent was 
evaporated under a steam of air to yield cis-[Rh2(CH3COO)2(CH3CN)6][BF4]2 (23.8 mg, 
0.032 mmol, 72 % yield) as an bright purple solid. The product was characterized by 
1
H 
NMR (250 MHz, deuterium oxide). The NMR spectrum is shown in Figure 20. 
 
Figure 20. 
1
H NMR spectrum cis-[Rh2(CH3COO)2(CH3CN)6][BF4]2 (250 MHz, 
deuterium oxide) 
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The product was also characterized by ESI-MS. The mass spectrum of the product is 
shown in Figure 21. The base peak, [Rh2(CH3COO)2(CH3CN)3F]
+
, was observed at m/z 
= 466.0, and the peak at m/z = 429.9 corresponds to [Rh2(CH3COO)2(CH3CN)2F]
+
. The 
identity of the other peaks remains unknown. 
 
Figure 21. ESI-MS spectrum of cis-[Rh2(CH3COO)2(CH3CN)6][BF4]2. The base peak ion 
corresponds to the formula [Rh2(CH3COO)2(CH3CN)3F]
+
, seen at m/z = 466.0 
3.2.2.3 Synthesis of cis-[Rh2(CH3COO)2(bpy)(CH3CN)4][BF4]2 
The synthesis of cis-[Rh2(CH3COO)2(bpy)(CH3CN)4][BF4]2 was attempted according a 
published procedure
16
. The complex cis-[Rh2(CH3COO)2(CH3CN)6][BF4]2 (2.5 mg, 3.4 
µmol) was reacted with bpy (0.6 mg, 3.8 µmol) in acetonitrile (1.0 mL) at room 
temperature for 24 h. The reaction was treated with excess diethyl ether and a precipitate 
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formed. The mixture was centrifugated and the supernatant was removed with a pipette 
and discarded. The precipitate was washed again with diethyl ether, centrifugated and the 
solvent was removed and discarded. The resulting solid was transferred to a vial with a 
minimal volume of acetonitrile and a 
1
H NMR (250 MHz, deuterium oxide) spectrum 
was collected, which showed that the reaction was unsuccessful. The NMR spectrum 
showed the presence of multiple products and impurities including unreacted bpy and 
starting dirhodium complex, bis-bpy adduct, bpy bound in the axial position, etc among 
other unknown species. 
Because cis-[Rh2(CH3COO)2(CH3CN)6][BF4]2 is photoactive
9
, the complex was reacted 
with bpy in the dark under conditions similar conditions to those described. This reaction 
was also unsuccessful. In another attempt to synthesize the cis-
[Rh2(CH3COO)2(bpy)(CH3CN)4][BF4]2 complex, a solution of cis-
[Rh2(CH3COO)2(CH3CN)6][BF4]2 (10 mg, 13.4 µmol) and bpy (2.2 mg, 13.7 µmol) in 
acetonitrile (2 mL) was irradiated with 455 nm light for 4 h, monitoring the reaction by 
1
H NMR (400 MHz, deuterium oxide) after 0.5 h, 1 h, 2 h, and 4 h. The NMR spectra 
again showed a complex mixture of products. 
Lastly, a solution of cis-[Rh2(CH3COO)2(CH3CN)6][BF4]2 (10 mg, 13.4 µmol) and bpy 
(2.2 mg, 13.7 µmol) was refluxed for 24 h in acetonitrile (5 mL). A similar reaction was 
performed in methanol, a weaker coordination ligand, refluxing for 7 days. After 
inspection by 
1
H NMR (400 MHz, deuterium oxide) spectroscopy, both reactions failed 
to yield primarily cis-[Rh2(CH3COO)2(bpy)(CH3CN)4][BF4]2. 
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3.3 Discussion 
Like the H,H complex, cis-[Rh2(CH3COO)2(CH3CN)6]
2+
 also undergoes thermal 
exchange of the Rh-CH3CNax ligands and covalent binding is not triggered by this 
exchange
9
. Photolysis studies by electronic absorption showed that two Rh-CH3CNeq 
bound to the same rhodium atom are exchanged for water
9
, which generates cis-
[Rh2(CH3COO)2(CH3CN)2(H2O)4]
2+
, the activated complex that binds to DNA 
covalently. DNA binding assay of the cis-[Rh2(CH3COO)2(CH3CN)6]
2+
  complex showed 
no decrease in mobility of DNA in the dark, and binding upon irradiation. Moreover, a 
34-fold increase in cell death upon irradiation
 
was observed with Hs-27 human skin 
cells
9
.  
The attempt to exchange two Rh-CH3CNeq ligands in cis-[Rh2(CH3COO)2(CH3CN)6]
2+ 
for bidentate bpy has been so far unsuccessful. It has been shown that the formation of 
the cis-[Rh2(CH3COO)2(bpy)(CH3CN)4]
2+ 
is photoinduced in the reaction of cis-
[Rh2(CH3COO)2(CH3CN)6]
2+ 
and bpy in 1:1 ratio
17
. However, these studies did not 
involve the isolation of the mono-bpy dirhodium bis-acetate complex and were primarily 
performed at low concentration. 
Future studies of dirhodium bis-acetate complexes will involve the synthesis of cis-
[Rh2(CH3COO)2(N-N)(CH3CN)4]
2+ 
(N-N = bpy, dpq, dppz, dppn) and the photolysis 
studies of these compounds to determine if they can be activated upon irradiation by the 
exchange of the remaining Rh-CH3CNeq ligands. In addition, it has to be determined if the 
dpq, dppz, and dppn analogs of the series can intercalate between the DNA bases to 
achieve dual-binding. 
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Chapter 4: Conclusions 
 
     Preliminary experiments have shown that dirhodium bis-amidate complexes have a 
promising potential as dual-binding photodynamic therapy agents. The successfully 
synthesized model complex H,H-bpy was shown to bind to DNA upon irradiation. This 
indicates that the other complexes of the series, H,H-dpq and H,H-dppz have high 
possibilities of also binding to DNA upon activation by light. Future work regarding 
these complexes will include the study of the intercalating ability of the dpq and dppz 
ligands bound to the dirhodium core. It has yet to be shown whether H,H-dpq and H,H-
dppz are inactive in the dark, since the increased affinity for DNA due to the extended π-
system may affect the activity of the complexes. 
Regarding the dirhodium bis-acetate complexes, future work will involve the synthesis of 
the complexes of the series cis-[Rh2(CH3COO)2(N-N)(CH3CN)4]
2+ 
, where N-N = bpy 
(the model complex for no intercalation), dpq, dppz, and dppn. Since the precursor 
molecule cis-[Rh2(CH3COO)2(CH3CN)6]
2+ 
has shown desired photodynamic therapy 
agent features, these complexes may also have a strong potential as photoactivated dual-
binding agents. 
Both types of complexes, dirhodium bis-acetate and dirhodium bis-amidate complexes 
have the potential to be the next generation photodynamic therapy agents, which may 
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represent a breakthrough for transition metal complexes as new drugs for treating 
malignant conditions based on their novel mode of action. 
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